Mid-March 2026: Peptide Sciences Is Gone, the FDA Hasn't Moved, and the Grey Market Is Collapsing

Peptide Sciences Is Gone

On March 6, 2026, at approximately 2:00 PM Eastern, peptidesciences.com went dark. The site now displays a single message: the company “voluntarily” shut down operations and discontinued all product sales. No forwarding address. No refund process. No explanation beyond that single word — voluntarily.

Peptide Sciences was the largest and most recognized grey-market research peptide vendor in the United States. According to e-commerce analytics firm Grips Intelligence, the company was generating $7.4 million in monthly sales as recently as December 2025, with over one million website sessions per month. That’s not a small shop. That’s the anchor tenant of an entire market segment, and it’s gone.

We’ve published a detailed analysis of the shutdown, but the key points bear repeating here: no single event caused the closure. Three forces converged — federal enforcement pressure (FDA warning letters, DOJ prosecutions, ITC exclusion orders), Big Pharma litigation (Eli Lilly’s ITC campaign, Novo Nordisk’s parallel actions), and quality concerns documented by Finnrick’s independent testing.

The Finnrick Data Is Damning — and Illuminating

Finnrick analyzed 123 samples across ten Peptide Sciences products. The results tell a story of a vendor that was excellent at some things and failing at others:

Passed well: Ipamorelin (A rating, 9.2/10 average), PT-141 (A), BPC-157 (A, 7.8/10)

Failed badly: CJC-1295 (E rating, 4.3/10), Tesamorelin (E), and most damning — retatrutide received a failing E rating across 37 tested samples, with a counterfeit detection flagged among November 2025 samples.

This is the uncomfortable reality the grey market doesn’t want to talk about: even the “best” vendors had inconsistent quality. A customer buying BPC-157 from Peptide Sciences was getting a high-quality product. The same customer buying CJC-1295 was getting something that barely qualified. And anyone buying retatrutide was playing roulette with counterfeits.

PeptideExaminer rated Peptide Sciences B+ — the highest grade in our vendor directory. We stand by that assessment based on the data available at the time. But the Finnrick results, combined with the shutdown, reinforce a point we’ve made repeatedly: even the best grey-market vendors operate without the quality controls that regulated manufacturing provides. B+ in the grey market is not the same as pharmaceutical-grade.

What It Signals for the Market

Dr. Steven Murphy, writing on his Substack, called the closure “something quietly seismic.” Jay Campbell of BioLongevity Labs was more direct: “The federal government — DOJ, FBI, and FDA — has decided that RUO peptide manufacturing and distribution can no longer sell, manufacture, or distribute injectable peptides. Anything injectable is now toast.”

Peptide Sciences is not the first domino. At least seven research peptide companies shut down in 2025, including Amino Asylum (FDA warehouse raid, June 2025). All American Peptide’s owners pleaded guilty to conspiracy charges with $3+ million in forfeitures. Tailor Made Compounding pleaded guilty and faced $1.79 million in forfeiture. The pattern is unmistakable: the grey-market model for injectable peptides is dying, and the vendors who haven’t closed voluntarily are either ignoring the warning signs or hoping to cash out before the door slams.

If you’re still ordering from grey-market vendors: understand the trajectory. Every major enforcement action to date has followed a predictable pattern — warning letters, then civil action, then criminal prosecution. The vendors still operating have not been cleared. They simply haven’t been reached yet.

Two Weeks Later: Where Is the FDA Reclassification?

On February 27, RFK Jr. announced on Joe Rogan that approximately 14 of 19 Category 2 peptides would be reclassified to Category 1. He said it would happen “in the next couple of weeks.”

It is now March 14. The FDA has not published an updated Category 2 list. No formal rulemaking has been initiated. No official guidance has been issued. The legal status of Category 2 peptides is unchanged.

This matters because the internet has already declared victory. Clinic websites are already advertising “legally available” peptide therapy. Telehealth platforms are marketing compounded BPC-157. Peptide influencers are celebrating the “ban reversal.”

None of that is technically accurate yet. An HHS Secretary’s statement on a podcast is not a regulatory action. Until the FDA formally publishes an updated list, the Category 2 restrictions remain in effect. Compounding pharmacies that begin preparing Category 2 peptides based on the announcement alone are operating in a legal grey area.

That said, the announcement has had real market effects:

Hims & Hers stock surged on the news (they confirmed a peptide product pipeline on their February 23 earnings call)
Compounding pharmacy associations are preparing for reclassification
Multiple telehealth platforms have launched or expanded peptide programs
SEO competition for “BPC-157 legal” and “peptides legal 2026” has intensified dramatically

Our position remains the same as when we first analyzed the announcement: the reclassification is encouraging but not yet real. Wait for the FDA to publish. Don’t make purchasing decisions based on a podcast appearance.

The SAFE Drugs Act: A New Threat to Research Chemicals

Introduced in early 2026, the Strengthening Accountability For Enforcement (SAFE) Drugs Act would prohibit the sale of research chemicals identical to FDA-approved drugs without a New Drug Application. If passed, this would directly target the “research use only” business model that the entire grey-market peptide industry depends on.

The bill targets the legal fiction at the heart of the grey market: vendors sell compounds at human-use doses, in human-use formats, marketed through channels that target human consumers, with disclaimers that say “not for human consumption.” The FDA’s Intended Use Doctrine already looks past these disclaimers (as demonstrated in the All American Peptide and Tailor Made Compounding convictions), but the SAFE Drugs Act would make the prohibition explicit and statutory rather than regulatory.

Combined with the ongoing DOJ prosecutions and ITC exclusion orders, the legislative and regulatory walls are closing in on the research chemical model from every direction simultaneously.

The Mainstream Media Wave Continues

Yesterday (March 13), MMM Online — a major pharmaceutical industry trade publication — published “Get ready for the peptides gold rush,” describing peptides as “a foundational part of the DIY health movement” and noting that Rogan reaches “one of the largest male audiences in media — roughly 80% of his listeners are men.”

This follows the wave we documented in our early March roundup: TIME, MIT Technology Review, STAT News, NPR, Science-Based Medicine, Undark, and Gizmodo all ran major peptide pieces in February and early March. The mainstream media attention is not slowing down — it’s accelerating.

For consumers, this media attention is a double-edged sword. It increases awareness and puts pressure on regulators to provide clear pathways for access. But it also attracts newcomers who don’t understand the quality, safety, and regulatory nuances — exactly the audience most vulnerable to bad vendors, misleading marketing, and unsafe practices.

What You Should Do Right Now

If you were a Peptide Sciences customer: Do not buy from any site claiming to be Peptide Sciences. Finnrick confirmed on March 6 that any site still selling under the Peptide Sciences name is fraudulent. If you have unfulfilled orders, initiate a chargeback with your bank immediately.

If you’re using grey-market peptides: The trend is unmistakable. Federal enforcement is intensifying, not easing. The vendor you’re buying from today may not exist next month. Plan your transition to legitimate channels — compounding pharmacies, telehealth platforms, or FDA-approved alternatives where they exist.

If you’re waiting for the reclassification: Continue waiting for the formal FDA publication before making any changes. The announcement is encouraging. The reality is not yet here. When it does arrive, we’ll have a comprehensive guide to accessing peptides through legitimate compounding pharmacies ready to publish.

If you’re new to peptides: This is actually the safest moment in years to begin. Not because of the reclassification announcement, but because the collapse of the grey market is pushing the industry toward legitimate, regulated channels. A physician consultation and a compounding pharmacy prescription is more accessible and more reliable than a grey-market website that might disappear tomorrow.

Market Intelligence

Metric	Data Point	Source
Peptide Sciences monthly revenue (Dec 2025)	$7.4 million	Grips Intelligence
Peptide Sciences monthly sessions	1M+	Grips Intelligence
Chinese peptide imports to US (first 3Q 2025)	$328 million (~2x YoY)	Trade data
Online peptide advertising increase since 2022	+678%	Industry analysis
Research peptide vendors shut down in 2025	7+	PeptideExaminer tracking
FDA warning letters to peptide vendors (Sept 2025)	50+	FDA enforcement records
Days since RFK reclassification announcement	15	—
Formal FDA publications since announcement	0	FDA.gov

PeptideExaminer tracks regulatory developments, enforcement actions, and market dynamics in real time. We don’t sell peptides. We tell you the truth about them.